Cargando…

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells

Detalles Bibliográficos
Autores principales:	Maurer, Katie, Kim, Haesook T., Garrity, Heather M., Liney, Deborah, Cutler, Corey, Antin, Joseph H., Koreth, John, Ritz, Jerome, Shapiro, Roman M., Romee, Rizwan, Ho, Vincent T., Gooptu, Mahasweta, Soiffer, Robert J., Wu, Catherine J., Nikiforow, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241844/ https://www.ncbi.nlm.nih.gov/pubmed/36595453 http://dx.doi.org/10.1182/bloodadvances.2022009231

Ejemplares similares

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
por: Kim, Haesook T., et al.
Publicado: (2021)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
por: Maurer, Katie, et al.
Publicado: (2021)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
por: Kekre, Natasha, et al.
Publicado: (2017)

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome
por: Brown, Jennifer R., et al.
Publicado: (2012)

Translational and clinical advances in acute graft-versus-host disease
por: Gooptu, Mahasweta, et al.
Publicado: (2020)

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
por: Shapiro, Roman M., et al.
Publicado: (2022)

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
por: Whangbo, Jennifer S., et al.
Publicado: (2022)

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults
por: Politikos, Ioannis, et al.
Publicado: (2015)

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results
por: Koreth, John, et al.
Publicado: (2018)

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
por: Maurer, Katie, et al.
Publicado: (2021)

(90)Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma
por: Abou-Nassar, Karim E., et al.
Publicado: (2011)

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?
por: Abel, Gregory A., et al.
Publicado: (2020)

Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation
por: Zorn, Emmanuel, et al.
Publicado: (2004)

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
por: Li, L, et al.
Publicado: (2014)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation
por: Karantanos, Theodoros, et al.
Publicado: (2019)

Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic
por: Mfarrej, B., et al.
Publicado: (2021)

Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease
por: Donato, Veronica, et al.
Publicado: (2022)

Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
por: Szyska, Martin, et al.
Publicado: (2016)

The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations
por: Zhao, Chenchen, et al.
Publicado: (2021)

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation
por: Teshima, Takanori, et al.
Publicado: (2023)

Long-term health outcomes of allogeneic hematopoietic stem cell transplantation
por: Kelkar, Amar H., et al.
Publicado: (2023)

Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation
por: Qayed, Muna, et al.
Publicado: (2022)

Autologous cellular therapy for myeloma: Giving ex vivo expanded NK cells their due
por: Shapiro, Roman M., et al.
Publicado: (2022)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Self-retained cryopreserved amniotic membrane in treating acute ocular graft-versus-host-disease (oGVHD)
por: Yin, Han Y., et al.
Publicado: (2020)

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b1m9ha2g9l547710g6fn026g7b